← Back

Beijing Konruns Pharmaceutical Co Ltd

Beijing Konruns Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceuticals in China and internationally. Its product agkistrodon halys hemocoagulase is sold under the Suling trade name. The company is also developing drug candidates, including ZY5301, which is in phase 3 clinical trials for chronic pelvic pain in sequelae of pelvic inflammatory disease, and KC1036, which is in phase 2 clinical trials for solid tumors. Founded in 2003, it is headquartered in Beijing, China.

Country
Price · split & dividend adjusted
News & notes moving 603590.CG
603590.CG▲

Konruns Pharmaceutical 2026 Interim Report Net Profit 95.7226 Million Yuan

Konruns Pharmaceutical released its 2026 interim report, with total operating revenue of 463 million yuan and net profit attributable to the parent company of 95.7226 million yuan. Net cash inflow from operating activities was 4.5587 million yuan, the asset-liability ratio was 15.68%, gross margin was 89.81%, ROE was 3.01%, and diluted earnings per share was 0.61 yuan. The number of shareholders was 15,300, and the top ten shareholders held 54.42% of total share capital.
603590.CG ▲
Jiemian·24dRead more →
603590.CG

Konruns Pharmaceutical first-half net profit attributable to parent rises 5.1% to 95.72 million yuan

Konruns Pharmaceutical released its 2026 interim report, showing first-half net profit attributable to the parent of 95.72 million yuan, up 5.1% year on year. Operating revenue was 463 million yuan, up 0.4% year on year, while net profit attributable to the parent after deducting non-recurring items was 92.18 million yuan, down 4.2% year on year. Second-quarter net profit attributable to the parent was 48.51 million yuan, up 4.2% year on year. Research and development spending was 64.98 million yuan, up 29.03% year on year, and the marketing registration application for its core pipeline candidate ZY5301 was accepted in April 2026.
603590.CG
财中社·25dRead more →
603590.CG▲

Konruns Pharmaceutical first-half net profit attributable to shareholders reaches 95.7226 million yuan, up 5.14% year on year

Konruns Pharmaceutical released its 2026 semi-annual report, achieving net profit attributable to shareholders of approximately 95.7226 million yuan in the first half, up 5.14% year on year. The company achieved operating revenue of approximately 463 million yuan in the same period, up 0.42% year on year. During the reporting period, research and development investment was approximately 64.9779 million yuan, up 29.03% year on year, accounting for 14.04% of operating revenue, with the development progress of core pipeline drug candidates continuing to advance rapidly. Konruns Pharmaceutical focuses on the research and development, production, and sales of innovative drugs.
603590.CG ▲
北京商报·25dRead more →
© 2026 MarketDXAsset